LONDON – Oxford University announced Saturday that it is resuming a trial for a coronavirus vaccine that will be presented with pharmaceutical company AstraZeneca, a resolution that occurs days after the examination was discontinued after an informed side effect on a British patient.
In a statement, the university showed a reboot at all of its test sites in the UK after regulators gave go-ahead after Sunday’s break.
“The indefinite review procedure has come to an end and following the recommendations of the indefinite protection review committee and the British regulator, MHRA, trials will resume in the UK,” he said.
The vaccine being developed through Oxford and AstraZeneca is widely recognized as one of the leading applicants among dozens of test-stage coronavirus vaccines worldwide.
UK Health Secretary Matt Hancock welcomed the reboot and said in a tweet it was “good news for everyone” that the essay would “be operational again. “
The university said that in giant trials like this, “some participants are expected to become ill and that each case will have to be thoroughly evaluated to ensure a full protection assessment.
He said about 18,000 international people have won his vaccine so far. Volunteers from some of the most affected countries (Britain, Brazil, South Africa and the United States) are participating in the trial.
Brazilian fitness regulator Anvisa announced saturday that he had approved the resumption of the “Oxford vaccine” in the South American country after receiving official data from AstraZeneca.
Although Oxford reveals data on the patient’s illness due to the confidentiality of the participants, an AstraZeneca spokesperson said this week that a woman had developed severe neurological symptoms that caused the break. Specifically, the woman developed symptoms consistent with transverse myelitis, a rare disease. inflammation of the spinal cord.
The university insisted that it is “committed to protecting our participants and the criteria for conduct in our studies and will continue to monitor protection closely. “
Disruptions in drug trials are and the suspension of transitoryness caused a sharp drop in the percentage value of AstraZeneca after Tuesday’s announcement.
The Oxford-AstraZeneca test was already suspended in July for several days after a player developed neurological symptoms that turned out to be an undiagnosed case of sclerosis that researchers declared unrelated to the vaccine.
During the third and final level of testing, researchers look for any symptoms of imaginable side effects that may not have been found in previous research with patients. Due to their giant size, studies are considered the most important exploration phase for tripping. Trials also evaluate efficacy by monitoring who gets sick and who is not among patients receiving the vaccine and those receiving a dummy injection.
Dr. Charlotte Summers, senior professor of intensive care medicine at the University of Cambridge, said the breakup is a sign that the Oxford team prioritizes protection issues, but that it leads to “a lot of unnecessary speculation. “
“To combat the global COVID-19 pandemic, we want to expand vaccines and treatments that other people feel comfortable using, so it is imperative for public confidence that we stick to the evidence and do not draw conclusions until the data is available. She said.
Scientists and stakeholders around the world, as well as experts from the World Health Organization, have sought to control expectations for imminent progress for coronavirus vaccines, noting that vaccine trials are rarely simple.
Italian Health Minister Roberto Speranza welcomed the resumption of the vaccine trial, but warned that caution is still necessary.
“Science is in paintings to give effective and global remedies and vaccines,” he said. “In the meantime, the key remains our behavior. “
Italy, which is point 0 of the epidemic in Europe, is one of the leading countries investing in the AstraZeneca vaccine.
Two vaccines are undergoing mass last-stage testing in the United States, one manufactured through Moderna Inc. and the other through Pfizer and BioNTech in Germany.
Oxford and AstraZeneca resume testing the COVID-19 Wire Services / New York Post vaccine.